SynthesisAmerican journal of epidemiology2017
TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences.
Synthesis in American journal of epidemiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 89 citations in OpenAlex.
- The Genitourinary Pathology Society and International Society of Urological Pathology Joint Expert Consultation Recommendations on intraductal carcinoma of the prostate.Histopathology · 2026Guideline
- Etiology of prostate cancer with the TMPRSS2:ERG fusion: A systematic review of risk factors.International journal of cancer · 2025Pooled it
- Prevalence and clinical application ofAsian journal of andrologyPooled it
- Heterogeneity of urinary system tumors: novel avenues for targeted therapy and precision medicine.Journal of advanced research · 2026Review
- Epigenetic modulation of prostate cancer disparities in men with African ancestry.Nature reviews. Urology · 2026Review
- Clinical biochemical significance of STAT6, ERG, and miR-647 expression in prostate cancer: Associations with tumor aggressiveness and patient prognosis.Journal of medical biochemistry · 2026Article
- Racial variation in the advanced prostate cancer genome.Prostate cancer and prostatic diseases · 2025Article
- Deep Sequencing Reveals Novel Mutations inInternational journal of molecular sciences · 2025Article
- Article
- A retrospective analysis of tissue, liquid, and germline testing in Hispanic and non-Hispanic men with advanced hormone-sensitive prostate cancer.Urologic oncology · 2025Article
- Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer.Prostate cancer and prostatic diseases · 2025Review
- Predicting prostate cancer metastasis in Ghana: Comparison of multiparametric and PSA models.PloS one · 2025Article
- Exploring therapeutic applications ofFrontiers in oncology · 2025Review
- A cross-sectional study of ERG expression and the relationship with clinicopathological features of Prostate cancer in Southwestern Uganda.Diagnostic pathology · 2024Article
- Acquired copy number variation in prostate tumours: a review of common somatic copy number alterations, how they are formed and their clinical utility.British journal of cancer · 2024Review
- Clinical Biofluid Assays for Prostate Cancer.Cancers · 2023Review
- Bipolar Androgen Therapy: When Excess Fuel Extinguishes the Fire.Biomedicines · 2023Review
- Characterization and evaluation of gene fusions as a measure of genetic instability and disease prognosis in prostate cancer.BMC cancer · 2023Article
- Metabolic syndrome is associated with aggressive prostate cancer regardless of race.Cancer causes & control : CCC · 2023Article
- Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 2 countries.
Funding
Abstract
The prevalence of fusions of the transmembrane protease, serine 2, gene (TMPRSS2) with the erythroblast transformation-specific-related gene (ERG), or TMPRSS2:ERG, in prostate cancer varies by race. However, such somatic aberration and its association with prognostic factors have neither been studied in a West African population nor been systematically reviewed in the context of racial differences. We used immunohistochemistry to assess oncoprotein encoded by the ERG gene as the established surrogate of ERG fusion genes among 262 prostate cancer biopsies from the Ghana Prostate Study (2004-2006). Poisson regression with robust variance estimation provided prevalence ratios and 95% confidence intervals of ERG expression in relation to patient characteristics. We found that 47 of 262 (18%) prostate cancers were ERG-positive, and being negative for ERG staining was associated with higher Gleason score. We further conducted a systematic review and meta-analysis of TMPRSS2:ERG fusions in relation to race, Gleason score, and tumor stage, combining results from Ghana with 40 additional studies. Meta-analysis showed the prevalence of TMPRSS2:ERG fusions in prostate cancer to be highest in men of European descent (49%), followed by men of Asian (27%) and then African (25%) descent. The lower prevalence of TMPRSS2:ERG fusions in men of African descent implies that alternative genomic mechanisms might explain the disproportionately high prostate cancer burden in such populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.